Recent findings from an NCI-supported clinical trial provide helpful information for doctors and their patients with locally advanced head and neck cancer who can’t be given the chemotherapy drug cisplatin.
The simple act of regularly asking young patients about their symptoms during cancer treatment can help them get more supportive care and reduce distressing side effects, according to the recent results of two clinical trials.
Lacey Koelling was diagnosed with paraganglioma tumors in 2018. When her tumors began to spread 5 years later, she enrolled in an NIH trial to contribute to research on this rare cancer.
Clinical Trials Information for Patients and Caregivers
Misunderstandings about clinical trials might steer people away from participating in them. But knowing the facts on this page can help you make an informed decision.
Most clinical trials follow similar steps before, during, and after you sign up to participate. This new page offers information about what to expect before you enroll, while taking part in a trial, and after the trial is over.
This phase 1 trial is testing CAR T-cell therapy that targets a protein called GPC3, which is often present at high levels on the surface of liver cancer cells. People with liver cancer that test positive for GPC3 and have not improved with chemotherapy will get the immunotherapy procedure. Doctors want to see if CAR T-cell therapy using T cells genetically modified to recognize GPC3 is safe. They will also look for evidence that it can shrink tumors.
This clinical trial is comparing two different surgeries to see how well they work to reduce the risk of ovarian cancer in people at high risk because of an inherited genetic mutation. People with mutations in their BRCA1 gene will have surgery to either remove both their ovaries and fallopian tubes or just their fallopian tubes. Doctors want to see if removing only the fallopian tubes is as effective at preventing ovarian cancer while preserving some ovarian function.
This phase 1/2 clinical trial is testing a drug called zotiraciclib for people with high-grade gliomas with certain gene mutations and whose cancer has not responded to earlier treatments. Doctors want to determine the best dose for this drug and see if it helps keep their disease from getting any worse.
